通过扰乱基和RAD51乳酸化,准抗的卵巢癌
Chenggong Sun1,2,3, Xiao Li1,2,3, Qiuli Teng1,2
1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, PR China.
Theranostics
|March 14, 2025
概括
基斯乳化,特别是H3K9la,通过增强DNA修复,驱动卵巢癌中的抗性. 抑制H3K9la或其调节器GCN5使瘤对化疗重新敏感,提供了一种新的治疗策略.
科学领域:
- 生物化学和分子生物学
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 卵巢癌具有很高的死亡率和频繁的白金耐药性.
- 乳化是一种新兴的翻译后修饰,在生物学上扮演着不同的角色.
- 乳化对抗性的作用在很大程度上仍未被探索.
研究的目的:
- 为了研究基因组和非基因组乳化在卵巢癌中抗性的参与.
- 为了确定克服抗性的潜在治疗目标.
主要方法:
- 在TCGA数据上进行基因组丰富分析 (GSEA),以确定与乳化相关的途径.
- 西部涂抹,免疫组织化学,CCK8,流细胞计和克隆基因分析,以评估H3K9la表达和药物反应.
- 用于机械和体内验证的CHIP-seq,CHIP-qPCR,LC-MS/MS,Co-IP和异种移植模型 (细胞系和PDX).
主要成果:
- 在抗性卵巢癌中H3K9la升高与预后不佳相关.
- H3K9la直接对RAD51和BRCA2进行上调,促进同源重组 (HR) 修复和对西斯普拉丁的抗性.
- RAD51K73la增强HR修复;GCN5调节H3K9la和RAD51K73la;GCN5抑制在体内增强西斯的疗效.
结论:
- 基因组和RAD51乳化是卵巢癌中同源重组修复和抗性的关键调解者.
- 准H3K9la或GCN5是一个有前途的治疗策略,可以克服抗性并改善患者的治疗结果.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K